Myeloproliferative neoplasms (MPN) |
Chronic myeloid leukemia (CML), BCR-ABL1+ |
Chronic neutrophilic leukemia (CNL) |
Polycythemia vera (PV) |
Primary myelofibrosis (PMF) |
PMF, prefibrotic/early stage |
PMF, overt fibrotic stage |
Essential thrombocythemia (ET) |
Chronic eosinophilic leukemia, not otherwise specified (NOS) |
MPN, unclassifiable |
Mastocytosis |
Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2 |
Myeloid/lymphoid neoplasms with PDGFRA rearrangement |
Myeloid/lymphoid neoplasms with PDGFRB rearrangement |
Myeloid/lymphoid neoplasms with FGFR1 rearrangement |
Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK2 |
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) |
Chronic myelomonocytic leukemia (CMML) |
Atypical chronic myeloid leukemia (aCML), BCR-ABL1− |
Juvenile myelomonocytic leukemia (JMML) |
MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) |
MDS/MPN, unclassifiable |
Myelodysplastic syndromes (MDS) |
MDS with single lineage dysplasia |
MDS with ring sideroblasts (MDS-RS) |
MDS-RS and single lineage dysplasia |
MDS-RS and multilineage dysplasia |
MDS with multilineage dysplasia |
MDS with excess blasts |
MDS with isolated del(5q) |
MDS, unclassifiable |
Provisional entity: Refractory cytopenia of childhood |
Myeloid neoplasms with germ line predisposition |
Acute myeloid leukemia (AML) and related neoplasms |
AML with recurrent genetic abnormalities |
AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1 |
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 |
APL with PML-RARA |
AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A |
AML with t(6;9)(p23;q34.1);DEK-NUP214 |
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM |
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1 |
Provisional entity: AML with BCR-ABL1 |
AML with mutated NPM1 |
AML with biallelic mutations of CEBPA |
Provisional entity: AML with mutated RUNX1 |
AML with myelodysplasia-related changes |
Therapy-related myeloid neoplasms |
AML, NOS |
AML with minimal differentiation |
AML without maturation |
AML with maturation |
Acute myelomonocytic leukemia |
Acute monoblastic/monocytic leukemia |
Pure erythroid leukemia |
Acute megakaryoblastic leukemia |
Acute basophilic leukemia |
Acute panmyelosis with myelofibrosis |
Myeloid sarcoma |
Myeloid proliferations related to Down syndrome |
Transient abnormal myelopoiesis (TAM) |
Myeloid leukemia associated with Down syndrome |
Blastic plasmacytoid dendritic cell neoplasm |
Acute leukemias of ambiguous lineage |
Acute undifferentiated leukemia |
Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 |
MPAL with t(v;11q23.3); KMT2A rearranged |
MPAL, B/myeloid, NOS |
MPAL, T/myeloid, NOS |
B-lymphoblastic leukemia/lymphoma |
B-lymphoblastic leukemia/lymphoma, NOS |
B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities |
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1 |
B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged |
B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 |
B-lymphoblastic leukemia/lymphoma with hyperdiploidy |
B-lymphoblastic leukemia/lymphoma with hypodiploidy |
B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH |
B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1 |
Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like |
Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP21 |
T-lymphoblastic leukemia/lymphoma |
Provisional entity: Early T-cell precursor lymphoblastic leukemia |
Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymphoma |